The integration will enable Leica’s BOND staining systems to simultaneously detect RNA and protein targets on the same tissue.

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Companion Cancer Diagnostics Market The rising incidence of cancer worldwide is a primary driver of the Global Companion Cancer Diagnostics ...

This blog explores the benefits of applying Large Language Models to extract information from pathology reports, allowing us to curate bespoke ...

A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to ...

The current standards for interrogating the molecular and genomic composition of tissue in situ ... in cancer. The full challenge of valuation occurs with whole-genome sequencing.

Expression matrices for CD45+ and CD45- were obtained, and 64 CD45+ and 64 CD45- samples were combined into 64 samples. Bulk-RNA sequencing data and clinical information for ESCC patients were ...

The proportion of patients being diagnosed with cancer at an early stage in England has risen to its highest ever level, according to new NHS analysis. Latest data on 13 of the most common cancers, ...

Panel A shows worldwide age-standardized incidence and mortality rates for cervical cancer in 2022. Data are from the GLOBOCAN database and were collated by the International Agency for Research ...